癌症相关血栓形成超过6个月的延长抗凝治疗:复发与出血率的系统综述
该系统综述筛选了2597篇文献,纳入11项研究、共3019例癌症相关静脉血栓栓塞症(VTE)患者,汇总分析指数事件后6至12个月期间的复发VTE和出血事件。结果显示该时间段内复发VTE总体发生率在1%至12%之间,6个月时存在残余静脉血栓且随机不接受抗凝治疗的患者亚组风险最高(13%至15%);6至12个月大出血发生率为2%至5%。结论认为VTE复发在6个月后仍常见,继续不同抗凝策略的安全性可接受,支持指南推荐对活动性癌症患者继续抗凝超过6个月。
要点
- 癌症相关VTE患者6至12个月复发VTE发生率在1%至12%之间,风险差异大。
- 6个月时存在残余静脉血栓且随机不接受抗凝治疗者复发风险最高(13%至15%)。
- 6至12个月大出血发生率为2%至5%,继续抗凝安全性可接受。
核心结论
- 癌症相关VTE在6个月后复发仍常见,继续不同抗凝策略的安全性可接受,表现为出血率较低。
- 这些发现支持指南推荐对活动性癌症患者继续抗凝治疗超过6个月。
研究设计与样本
- 系统综述,系统筛选MEDLINE、Embase、CENTRAL数据库,纳入报告癌症相关VTE诊断后6至12个月复发VTE和/或出血事件的研究。
- 共筛选2597篇文献,最终纳入11项符合预设纳入/排除标准的研究,报告3019例患者在指数VTE后6至12个月期间的数据。
- 因研究设计、 setting、患者队列特征、抗凝策略和结局发生率存在异质性,未计算总体结局率的定量估计。
主要发现
- 6至12个月期间复发VTE总体发生率差异很大(1%至12%)。
- 6个月时存在残余静脉血栓且随机不接受抗凝治疗的患者亚组复发风险最高(13%至15%)。
- 6至12个月报告的大出血发生率为2%至5%。
局限性
- 基于研究设计、 setting、患者队列特征、抗凝策略和结局发生率观察到的异质性,未计算总体结局率的定量估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cancer-associated venous thromboembolism (VTE) are recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months. Little data exist on extended treatment beyond 6 months. OBJECTIVE: To comprehensively summarize the best available evidence on incidence of recurrent VTE and major bleeding 6-12 months after the index event in patients with cancer-associated VTE. PATIENTS/METHODS: We systematically screened biomedical databases (MEDLINE, Embase, CENTRAL) to identify studies reporting recurrent VTE and/or bleeding events between 6 and 12 months after a diagnosis of cancer-associated VTE. Based on the observed heterogeneity in study design, setting, patient cohort characteristics, anticoagulation strategies, and outcome rates, no overall quantitative estimate of outcome rates was calculated. RESULTS: We screened 2597 publications and identified 11 eligible studies matching predefined in-/exclusion criteria, reporting on 3019 patients specifically during the 6- to 12-month period post-index VTE. Overall rates of recurrent VTE in this timeframe varied substantially (1%-12%), with the highest risk observed in the patient subgroup with residual vein thrombosis present at 6 months randomized to receive no anticoagulation (13%-15%). Reported rates of major bleeding between 6 and 12 months were between 2% and 5%. CONCLUSIONS: In this systematic review, we provide a comprehensive and structured summary of the best available evidence on recurrence and bleeding risk between 6 and 12 months after cancer-associated VTE. VTE recurrence remains common beyond 6 months and continuation of different anticoagulation strategies has an acceptable safety profile indicated by lower bleeding rates. These findings support guideline recommendations to continue anticoagulation treatment beyond 6 months in patients with active cancer.
引用
- Moik F, Colling M, Mahé I, et al. Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review. J Thromb Haemost. 2021. PMID: 34816583. doi:10.1111/jth.15599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。